Bayer To Update Yaz And Yasmin Labeling in the U.S.
Burg Simpson News Updates
Bayer is to add new safety information to the labels of its YAZ and Yasmin birth control pills sold in the United States. The label update follows the publication of two large studies of more than 120,000 women taking oral contraceptives in the U.S. and in Europe. On April 12, 2010, Bayer announced that the updated label will state that women taking YAZ and Yasmin have a comparable risk of developing venous thromboembolism (VTE) to those taking other combination oral contraceptives.
However, because the risk of VTE varies among types, or generations, of birth control pills, Bayer’s revised warning provides no meaningful information to women about the actual risk of VTE from Yasmin or Yaz. Bayer is currently facing more than 1000 lawsuits in the United States, brought by women who allege that their use of YAZ and Yasmin caused them to suffer a variety of health problems including, blood clots, heart attacks, strokes, respiratory problems and gallbladder disease amongst others.